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Abstract A heightened production of interleukin l/7 (IL-lb) has been reported in microglial-associated amyloid deposits in Alzheimer’s disease (AD) 
brains. These plaques are composed predominantly of pIA4 peptide derived from B-amyloid precursor protein QAPP). We demonstrate that 
short-term (1 h) IL-l/3-treatment increases /3APPs secretion and concomitantly decreases cell-associated BAPP in human H4 neuroglioma cells. 
Long-term (5 h) IL-1s treatment did not alter secreted or cell-associated BAPP content. In contrast, the secretion of BIACcontaining epitope was 
not affected by short-term IL-l/3 stimulation; however, long-term IL-1s treatment decreased the amount of /?/A4-containing epitope secreted from 
the cells. These results show that IL-l/3 modifies the processing and secretion of j?APP to exacerbate perhaps the neuropathology of AD. 
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1. Introduction 2. Materials and methods 
Alzheimer’s disease (AD) pathology is characterized by le- 
sions in brain regions important for intellectual function. The 
characteristic lesions of AD as well as Down’s syndrome are 
amyloid depositions in the brain parenchyma in selected re- 
gions and in its vasculature. The amyloid deposits are com- 
posed predominantly of pIA4 peptide [l], derived from the 
transmembrane regions of B-amyloid precursor protein @APP) 
by proteolytic cleavage [2]. The increased production of /I/A4 
in some individuals leads to early onset of AD [3,4], implicating 
jIIA4 peptide as a pathogenic factor in AD. 
2.1. Cell culture 
Prointlammatory cytokines may also be involved in AD [5,6]. 
For example, AD and Down’s syndrome brains contain 30-fold 
more interleukin-l-producing microglia and astrocytes as com- 
pared to age-matched controls [7]. At the transcriptional evel, 
interleukin l/I (IL-l/3) increases BAPP mRNA in primary cul- 
tures of astrocytes, cortical neurons and endothelial cells [5,8], 
but not in oligodendrocyte-derived cell lines [9]. These differ- 
ences in interleukin- 1 effects may reflect differences among cell 
lines. At the protein level, short-term IL-l/?-stimulation of glial 
and endothelial cell lines increases ecreted /IAPP (BAPP,) [lo] 
but appears to have little affect on pIA4 secretion [ 111. 
Human neuroglioma H4 cells (ATCC), producing high amounts of 
/J/A4 peptide [12], were cultured in DMEM (Gibco-BRL) containing 
10% FCS (Hyclone) in 100 mm tissue culture dishes (Falcon) at 2 x lo6 
cells/IO ml. After 48 h, the medium was discarded, and the cells were 
washed 3 times with Puck’s Saline (Gibco-BRL). The cells were then 
cultured in 4 ml of OptiMEM I Reduced Serum Medium (Gibco-BRL) 
and supplemented with recombinant human IL-lb (Genzyme) for 1 or 
5 h at 37°C 5% CO, or left untreated. The conditioned medium was 
collected, supplemented with protease inhibitors [13], frozen with dry 
ice and stored at -20°C. Cellular protein extracts were obtained after 
washing the cells 3 times in Puck’s Saline and lysing the cells in 0.7 ml 
lysis buffer (20 mM Tris, pH 8.6,1% Triton X-100) containing protease 
inhibitors [13]. The lysates were frozen with dry ice and stored at 
-20°C. 
2.2. Antibodies 
Murine monoclonal antibodies (MAb) 22Cl1, 6ElO and 4G8 have 
been described previously [1416]. MAb 22Cll recognizes the amino 
terminus of /3APP,; MAb 6ElO recognizes the carboxy terminus of 
j?APP, and the amino terminus of /VA4 peptide (residues l-16); and 
MAb 4G8 recognizes the mid-region of B/A4 peptide (residues 17-24) 
but not BAPP,. Protein G purified MAb 6ElO was biotinylated with 
NHS-LC-biotin (Pierce). 
In the present study, we examine the effect of IL-1s stimula- 
tion on the regulation of BAPP and jVA4-containing epitope 
secretion as well as cell-associated BAPP in a neuroglioma cell 
line. Our results suggest hat short-term IL-l/3 stimulation al- 
ters both secreted and cell-associated BAPP but does not affect 
the secretion of jVA4-containing epitope. However, long-term 
IL-l/3 stimulation does not alter secreted or cell-associated 
j3APP but decreases the secretion of /3lA4-containing epitope 
by about 50%. 
2.3. SDS-PAGE and Western blot analysis 
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Secreted and cell-associatedpAPP were detected by Western blot. H4 
conditioned medium was diluted 1:2 in SDS-PAGE reducing sample 
buffer and heated for 5 min at 95°C. Equal volumes were loaded onto 
412% Tris-glycine gels (Novex). Detergent-extracted cellular proteins 
were quantitated by the BCA protein assay (Pierce Chemical Co.). 
Equal amounts of protein (4 &15 ~1) were loaded per lane on 412% 
gels. Electrophoresis was performed at 100 V, and proteins were trans- 
ferred to nitrocellulose (Hybond-ECL, Amersham) [17]. The blots were 
blocked with 5% non-fat dry milk (Carnation) and then incubated with 
anti-j?APP MAb (22Cl1, 5 &ml). After washing, the blots were incu- 
bated with sheep anti-mouse Ig-HRP (Amersham, 1: 1500). All washes 
and dilutions of non-fat dry milk and antibodies were with TBST (20 
mM Tris, pH 8.0, 0.5 M NaCl, 0.1% Tween 20) for 1 h. Immunoreac- 
tivity was detected using Enhanced Chemiluminescence on X-OMAT 
LS film according to the manufacturer’s recommendations (ECL detec- 
tion reagents, Amersham). The entire procedure was performed at 
room temperature. The films were scanned using optical reflectance 
(Visage Electrophoresis Gel Analysis System, Version 4.6, Millipore), 
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and the integrated optical density (IOD) of each band was calculated. 
The data were analyzed by the Student’s r-test (Statview 512). All blots 
contained an internal untreated control to which treated samples were 
compared. The results are reported as/?APP relative units, which is the 
ratio of IL-l/?-treatment IOD/untreated control IOD. 
2.4. ELISA 
BIA4containing epitope was detected using a modified double anti- 
body capture immunoassay [14]. The ELISA is specific for amino acids 
1-28 of the pIA4 peptide but does not detect secreted BAPP. ELISA 
plates (MaxiSorb, Costar) were coated with 0.5 pg of MAb 4G8 in 10 
mM sodium carbonate, pH 9.6 overnight at 4°C and then blocked with 
1% BSA and 0.1% bovine y-globulinin TBST. Samples (freshly col- 
lected conditioned medium) and standards @/A4 peptide, residues l- 
40) were added to each well and incubated overnight at 4°C. The plates 
were washed and incubated with 50 ~1 of biotinylated MAb 6ElO 
(3 &ml in TBST, 1% BSA) for 1 h, washed, then incubated for an 
additional hour with 50 ~1 of avidin-alkaline phosphatase conjugate 
(1:5000 dilution into TBST, 1% BSA). The plates were washed 3 times 
with TBST before adding 100 ~1 of Attophos (JBL Scientific, Inc.) to 
each well. Fluorescent intensity was read using a Cytofluor 2350 mul- 
tiwell fluorescence plate reader (Millipore, 440 nm excitation filter, 
bandwidth 20 nm; 560 nm emission filter, bandwidth 20 nm; sensitivity 
2). For detecting low levels of /I/A4 (c 50 pg/ml), the plates were incu- 
bated overnight in the dark before analysis. The entire procedure xcept 
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Fig. 1. Short-term IL-IS treatment decreases cell-associated /IAPP. H4 cells were treated with IL-l/I (1 or 10 rig/ml) for (A) 1 h or (B) 5 h. Cellular 
protein was collected from separate dishes by detergent lysis, and 4 pg of each sample (soluble fraction) was loaded onto 412% gradient gels. After 
electrophoresis and transfer to nitrocellulose, the blot was probed with MAb 22Cll and MAb 6ElO and developed with ECL. (C) 113 kDa and (D) 
97 kDa immunoreactive bands were quantified by optical reflectance. *P < 0.05 compared to the untreated 1 h control, n = 3. 
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3. Results 
Cell-associated BAPP content was determined by Western 
blot analysis of detergent-extracted cellular proteins from H4 
cells. Immunoreactivity was measured using either MAb 22Cll 
or MAb 6ElO. MAb 22Cll detects both/3APP and the amyloid 
precursor-like protein (APLP); 6ElO detects/?APP but does not 
detect APLP which lacks pIA4 epitopes. In all samples, two 
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Fig. 2. Short-term IL-1B treatment enhances /?APP,. H4 cells were 
treated with IL-l/I (1 or 10 @ml) for (A) 1 h or (B) 5 h. The conditioned 
medium from separate dishes was loaded onto 412% gradient gels. 
After electrophoresis and transfer to nitrocellulose, the blots were 
probed with MAb 22Cll and MAb 6ElO and developed with ECL. (C) 
BAPP, immunoreactive bands were quantified by optical reflectance. 
The results are representative of4 experiments. *P c 0.05 compared to 
the untreated 1 h control, n = 3. 
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Fig. 3. Short-term IL-lb treatment does not affect /3/A4 secretion. 
Conditioned medium from IL-lb-treated and untreated H4 cells was 
assayed by ELISA for BIA4containing epitopes after 1 h or 5 h of 
cytokine treatment. The results are representative of 4 experiments. 
*P c 0.05 compared to the untreated 5 h control, n = 3. 
major bands of 113 and 97 kDa were detected suggesting APLP 
was not a major contributor to the immunoreactivity measured 
(Fig. lA,B). Smaller proteins were also detected, presumably 
representing partially translated or partially degraded /IAPP 
(data not shown). 
Short-term (1 hour) IL-l/3 treatment reduced the amount of 
the 113 kDa cell-associated form of /?APP in H4 cells as com- 
pared to untreated cells at 1 h (Fig. 1C). After long-term (5 h) 
IL-l/I treatment, H4 cells contained about the same amount of 
113 kDa cell-associated /IAPP as the untreated cells at 5 h. 
Short-term IL-$5 treatment reduced the content of the 97 kDa 
cell-associated form approximately 2-fold as compared to un- 
treated 1 hour control cells (Fig. 1D). After 5 h of IL-l/I treat- 
ment, the amount of the 97 kDa form was approximately the 
same as the untreated 5 h control cells. 
Culture medium was collected from IL-l/&stimulated and 
unstimulated H4 cells to determine the effect of IL-IS on 
BAPP,. IL-l/I [l-lo @ml] induced a maximal change after 1 
h in BAPP, as detected on Western blots (Fig. 2). All blots 
showed a band of immunoreactivity having an apparent size of 
- 113 kDa. The scanned blots show that H4 cells stimulated with 
IL-l/I for 1 h secreted approximately 5-fold more BAPP, than 
the unstimulated 1 h control cells (Fig. 2C). The actual amount 
ofpAPP, secreted into the medium over 5 h from untreated cells 
was about 8-fold greater than BAPP, content in the medium 
from untreated cells at 1 h (data not shown). In contrast, after 
5 h of IL-lb treatment, the content of/IAPP, in the medium was 
the same as that secreted from the corresponding untreated 
control cells (Fig. 2B,C). It appears after the initial burst of 
&4PP secretion at 1 h, IL-l/I treatment reduces the apparent 
rate at which BAPP is secreted from the cells. 
BlA4-containing epitope was measured in H4 conditioned 
medium by ELISA. H4 cells treated with IL-l/? for 1 h pro- 
duced the same amount of /3IA4-containing epitope as un- 
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treated cells cultured for 1 h (Fig. 3). H4 cells treated with IL-lb 
for 5 h produced approximately half of the amount of 
/VACcontaining epitope as unstimulated control cells cultured 
for 5 h. 
4. Discussion 
The increase measured in /?APP, after stimulation with IL-lb 
for 1 h (short-term) indicates that this proinflammatory cytok- 
ine enhances ecretion of j?APP. The secretion seems transcrip- 
tionally-independent since the transcription of the j?APP gene 
(> 400 kB) and the subsequent translation of the message (lOO- 
120 kDa) require more than 1 h as suggested by others [18,19]. 
Our results are consistent witH those of Buxbaum et al. who 
attributed enhanced secretion of j3APP by IL-l/3 to metabolic 
changes rather than to changes in transcriptional rate [lo]. We 
do not believe IL-l/I induced aberrant processing of /?APP. 
Immunoreactive BAPP, was detected on blots probed with 
MAb 6ElO but not MAb 4G8 (data not shown). Thus, IL-l@ 
appears to cause normal a-secretase cleavage of cell-associated 
BAPP to give rise to BAPP,. 
Short-term IL-l/3 treatment did not affect the quantity of 
/VACcontaining epitope secreted into the medium. This con- 
firms the observation by Buxbaum et al. [l l] that IL-l&induced 
/3APP, and /VACcontaining epitope secretion are not recipro- 
cally linked. This result is in marked contrast to the effects of 
muscarinic agonists and phorbol esters on j?APP and BIA4 
secretion [20-221. Thus, the fate of BAPP may depend on the 
second messengers activated by different receptor-ligand inter- 
actions. The nature of these signal transduction systems in- 
duced by IL-l/I are being explored. 
Our results suggest that the secretion of BIACcontaining 
epitope and /3APPs are not reciprocally related. Their secretory 
processes may be differentially affected by IL-l/I stimulation, 
and short-term IL-l,9 stimulation may have long-term effects 
on /3APP processing that are not initially reflected in BAPP 
secretion. This implies that more complicated metabolic proc- 
essing of /IAPP may occur under conditions not revealed in 
earlier studies using carbachol and phorbol esters. Moreover, 
the experiments hould be performed in other cell types to 
determine if the IL-$9 effect pertains only to the neuroglioma 
cells used here. 
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